3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1/2
1
Phase 1
1
Status
Terminated
2
Completed
2
Sponsor Class
INDUSTRY
4
OTHER
1
Study Type
Interventional
4
Sponsor
Cancer Type
Lymphoid
3
Other hematologic neoplasm
2
Conditions
Recurrence
3
Waldenstrom Macroglobulinemia
1
Lymphoma, Mantle-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, Hairy Cell
1
Burkitt Lymphoma
1
Interventions
Paclitaxel
337
pembrolizumab
332
Carboplatin
329
Cisplatin
276
Gemcitabine
264
Docetaxel
251
Bevacizumab
239
Nivolumab
230
Pemetrexed
210
Rituximab
183
Dexamethasone
183
Cyclophosphamide
169
Capecitabine
169
Trastuzumab
149
Fluorouracil
147
Ipilimumab
121
atezolizumab
118
Prednisone
117
Erlotinib Hydrochloride
116
Oxaliplatin
109
Cetuximab
104
Sunitinib
101
Leucovorin
97
Doxorubicin
97
Lenalidomide
93
Irinotecan
89
130-nm albumin-bound paclitaxel
84
durvalumab
77
Bortezomib
77
Azacitidine
73
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
INDUSTRY
×
Has results
×
brexucabtagene autoleucel
×
Clear all
NCT02601313
2026-03-18
ZUMA-2
Gilead Sciences
Phase 2
Completed
105 enrolled
33 charts
1 FDA
NCT05537766
2026-03-10
ZUMA-25
Gilead Sciences
Phase 2
Terminated
19 enrolled
28 charts
NCT02614066
2024-11-19
ZUMA-3
Gilead Sciences
Phase 1/2
Completed
125 enrolled
27 charts
1 FDA
NCT03624036
2023-11-18
ZUMA-8
Gilead Sciences
Phase 1
Terminated
16 enrolled
17 charts